Catching DDMAC's Eye: Leaving Out Risk Information Proves Risky Practice For ISTA

ISTA receives a second warning letter from FDA in just over a year for promotional material that omits risk information for its lead ophthalmic product.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet